• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Cerenis

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · November 22, 2011

The Board of Cerenis appoints Dr. Richard C. Pasternak as Non Executive Director

Internationally recognized expert brings over 30 years of experience in the field of cardiovascular disease TOULOUSE, France and ANN ARBOR, USA, 22 November 2011. Cerenis Therapeutics, a …

News · November 22, 2011

Cerenis Appoints John F. Paolini as Chief Medical Officer

Internationally recognized expert brings over 15 years of experience in drug development and commercialisation to treat cardiovascular disease Toulouse (France) and Ann Arbor (United States), 22 …

News · March 15, 2011

Cerenis Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome

TOULOUSE, France and ANN ARBOR, Michigan, March 15, 2011. Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact